BRIEF-Contravir expands Phase 2A trial of tenofovir exalidex to include doses above 100 mg

* Contravir Pharmaceuticals - plans to begin evaluating TXL

at 150 mg per day dosing and potentially higher dosing based on

TXL's performance

Read more